<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="771">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151120</url>
  </required_header>
  <id_info>
    <org_study_id>69HCL21_0806</org_study_id>
    <secondary_id>2021-A02187-34</secondary_id>
    <nct_id>NCT05151120</nct_id>
  </id_info>
  <brief_title>Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents</brief_title>
  <acronym>IFCC-TSH</acronym>
  <official_title>Harmonization of Thyroid-stimulating Hormone Immunoassays Reagents - Blood Collection From Patients With Thyroid Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Given the prevalence and gravity of thyroid disorders, timely diagnosis, initiation, and&#xD;
      monitoring of therapy are important to restrict the impact of the disease on public health.&#xD;
      Measurement of serum thyroid stimulating hormone (TSH) concentrations is an indispensable&#xD;
      tool to confirm the disease and clinical management.&#xD;
&#xD;
      Reference intervals (RI) reported along with the laboratory data are an integral part of the&#xD;
      interpretation process. Since many laboratory measurements are not yet comparable, RIs are&#xD;
      typically established for each assay and are considered assay-specific. In this context,&#xD;
      physicians who request test results from different laboratories are faced with challenges&#xD;
      owing to different RIs. Assay-specific RIs are also problematic for patients who are seen by&#xD;
      different doctors/different countries and more generally, assay-specific measurement results&#xD;
      limit the development of modern public health standards.&#xD;
&#xD;
      Paramount to the goal of using common RIs is the establishment of metrological traceability&#xD;
      of in vitro diagnostic (IVD) medical devices-also called standardization. As the&#xD;
      International Federation of Clinical Chemistry (IFCC) Committee for Standardization of&#xD;
      Thyroid Function Tests (C-STFT) members, the investigators decided to focus efforts on&#xD;
      immunoassays for TSH in partnership with the IVD industry.&#xD;
&#xD;
      Although a reference measurement procedure existed for free thyroxine, the investigators&#xD;
      considered this option for TSH unlikely and developed a pragmatic approach to harmonization&#xD;
      rather than standardization.&#xD;
&#xD;
      Harmonization is important in order to guarantee comparability of results obtained in&#xD;
      different laboratories. The harmonization process is conducted by assigning target values to&#xD;
      a large set of samples, based on the results obtained by as many IVD-manufacturers as&#xD;
      possible (ref 2). Important here is the fact that these samples must cover the full measuring&#xD;
      range of a TSH assay, and so it is necessary to include samples from people with thyroid&#xD;
      disease.&#xD;
&#xD;
      The primary objective of the study is the constitution of blood samples collection from&#xD;
      patients with thyroid disorders in order to harmonize several commercially available&#xD;
      immunoassays used for the determination of thyroid hormone concentrations in the blood.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of subjet included</measure>
    <time_frame>through study completion, an average of 18 months</time_frame>
    <description>The primary objective is to collect 100 blood samples that distributed into the followings groups:&#xD;
GROUP A: Hyperthyroid (N = 30) A1: 10 patients with suppressed TSH, around 0.01 mIU/L A2: 10 patients with TSH values between 0.01 - 0.1 mIU/L A3: 10 patients with TSH values between 0.1 - 0.4 mIU/L&#xD;
GROUP B: Euthyroid (N = 30) Patients (under treatment) with TSH values between 0.4 - 4 mIU/L&#xD;
GROUP C: Hypothyroid (N = 40) C1: 20 patients with TSH values between 4 - 50 mIU/L C2: 20 patients with TSH values &gt; 50 mIU/L up to 100 mIU/L.</description>
  </primary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Thyroid Disorders</condition>
  <condition>Thyroid Stimulating; Hormone, C</condition>
  <arm_group>
    <arm_group_label>Group A: Hyperthyroid</arm_group_label>
    <description>30 patients will be included and divided into three categories: A1: 10 patients with suppressed TSH, around 0.01 milli-international unit/liter (mIU/L) A2: 10 patients with TSH values between 0.01 - 0.1 mIU/L A3: 10 patients with TSH values between 0.1 - 0.4 mIU/L</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: Euthyroid</arm_group_label>
    <description>30 Patients (under treatment) with TSH values between 0.4 - 4 mIU/L will be included</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GROUP C: Hypothyroid</arm_group_label>
    <description>40 patients will be included and divided into two categories: C1: 20 patients with TSH values between 4 - 50 mIU/L C2: 20 patients with TSH values &gt; 50 mIU/L up to 100 mIU/L. Even distribution (if possible).</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>blood sample</intervention_name>
    <description>In practice the only intervention of the study is 49 mL extra blood along with the blood draw that is already planned for diagnosis/follow-up</description>
    <arm_group_label>GROUP C: Hypothyroid</arm_group_label>
    <arm_group_label>Group A: Hyperthyroid</arm_group_label>
    <arm_group_label>Group B: Euthyroid</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1 sample during routine venepuncture of 49 mL blood collection (7 x 7mL)&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The recruitment will be performed from the clinical cohort of thyroid disorder patients&#xD;
        followed at the Hospices Civils de Lyon Hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female ≥ 18 years of age&#xD;
&#xD;
          -  Body weight ≥ 62 kg&#xD;
&#xD;
          -  With a thyroid disorder (with high, low or normal TSH levels)&#xD;
&#xD;
          -  Competent to give non opposition after information&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt;18 years old&#xD;
&#xD;
          -  Those individuals previously enrolled into this clinical study&#xD;
&#xD;
          -  Individuals diagnosed with a severe non-thyroidal illness at physician's appreciation.&#xD;
             Defined as a state of dysregulation where levels of T3, T4, free triiodothyronine&#xD;
             (FT3) and/or free thyroxine (FT4) are abnormal although the Thyroid gland does not&#xD;
             appear to be dysfunctional. In practice, non-thyroidal illness (NTI) is reported to be&#xD;
             usually associated with critical illness or starvation. Examples: chronic renal&#xD;
             failure, liver cirrhosis, advanced (active) malignancy, sepsis, trauma, prolonged&#xD;
             fasting or starvation, heart failure, Myocardial infarction (MI), and any psychiatric&#xD;
             disorder.&#xD;
&#xD;
          -  Pregnancy - please note that pregnancy test is not needed, a declaration is&#xD;
             sufficient. The inclusion of a sample from a woman with an unidentified pregnancy will&#xD;
             not jeopardize the study.&#xD;
&#xD;
          -  Patient under guardianship and under legal protection&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>RAVEROT Véronique, MD</last_name>
    <phone>04.72.35.74.61</phone>
    <phone_ext>+33</phone_ext>
    <email>veronique.raverot@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service D'endocrinologie - Hôpital Louis Pradel - Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69 677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>ABEILLON Juliette, MD</last_name>
      <phone>04 72 11 93 01</phone>
      <phone_ext>+33</phone_ext>
      <email>juliette.abeillon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>ABEILLON Juliette, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Médecine Nucléaire - Hôpital Louis Pradel - Hospices Civils de Lyon</name>
      <address>
        <city>Bron</city>
        <zip>69 677</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>JANIER Marc, MD, PhD</last_name>
      <phone>04.72.11.02.50</phone>
      <phone_ext>+33</phone_ext>
      <email>marc.janier@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>JANIER Marc, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>November 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>November 25, 2021</last_update_submitted>
  <last_update_submitted_qc>November 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blood Sample collection</keyword>
  <keyword>TSH results harmonisation</keyword>
  <keyword>IVD-manufacturers</keyword>
  <keyword>Reference intervals</keyword>
  <keyword>Results harmonisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroid Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

